{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T21:17:45Z","timestamp":1783459065572,"version":"3.55.0"},"update-to":[{"DOI":"10.1002\/14651858.cd008946.pub2","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2020,7,7]],"date-time":"2020-07-07T00:00:00Z","timestamp":1594080000000}}],"reference-count":237,"publisher":"Wiley","issue":"7","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd008946.pub3","type":"journal-article","created":{"date-parts":[[2020,7,7]],"date-time":"2020-07-07T06:14:38Z","timestamp":1594102478000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Interventions for mycosis fungoides"],"prefix":"10.1002","volume":"2020","author":[{"given":"Arash","family":"Valipour","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Venereology and Allergology; Johann Wolfgang Goethe-University Hospital; Frankfurt am Main Germany"},{"name":"Evidence-Based Medicine Frankfurt, Institute of General Practice; Goethe University; Frankfurt Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"J\u00e4ger","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Venereology and Allergology; Johann Wolfgang Goethe-University Hospital; Frankfurt am Main Germany"},{"name":"Hautklinik; St\u00e4dtisches Klinikum Karlsruhe; Karlsruhe Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peggy","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Dermatology; University of California Davis; Sacramento CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jochen","family":"Schmitt","sequence":"additional","affiliation":[{"name":"Center for Evidence-Based Healthcare; Faculty of Medicine Carl Gustav Carus, Technischen Universit\u00e4t (TU) Dresden; Dresden Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Bunch","sequence":"additional","affiliation":[{"name":"c\/o Cochrane Skin Group; The University of Nottingham; Nottingham UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Weberschock","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Venereology and Allergology; Johann Wolfgang Goethe-University Hospital; Frankfurt am Main Germany"},{"name":"Evidence-Based Medicine Frankfurt, Institute of General Practice; Goethe University; Frankfurt Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2020,7,7]]},"reference":[{"issue":"3","key":"10.1002\/14651858.CD008946.pub3-BIB0001|cit1","first-page":"286-94","article-title":"A phase III study of lenalidomide maintenance after debulking therapy in patients with advanced cutaneous T-cell lymphoma - EORTC 21081 (NCT01098656): results and lessons learned for future trial designs","volume":"27","author":"Bagot","year":"2017","journal-title":"European Journal of Dermatology"},{"key":"10.1002\/14651858.CD008946.pub3-BIB0002|cit2","unstructured":"A phase III study of lenalidomide maintenance after debulking therapy in patients with advanced cutaneous T-Cell lymphoma clinicaltrials.gov\/ct2\/show\/NCT01098656"},{"issue":"3","key":"10.1002\/14651858.CD008946.pub3-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1111\/j.1365-2230.2004.01525.x","article-title":"A randomized cross-over study to compare PUVA and extracorporeal photopheresis in the treatment of plaque stage (T2) mycosis fungoides","volume":"29","author":"Child","year":"2004","journal-title":"Clinical & Experimental Dermatology"},{"issue":"Suppl 59","key":"10.1002\/14651858.CD008946.pub3-BIB0004|cit4","first-page":"16","article-title":"A randomised cross-over study to compare Puva and extracorporeal photopheresis (ECP) in the treatment of plaque stage (T2) mycosis fungoides","volume":"145","author":"Child","year":"2001","journal-title":"British Journal of Dermatology"},{"issue":"2","key":"10.1002\/14651858.CD008946.pub3-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1080\/09546630310019373","article-title":"Imiquimod 5% cream in the treatment of mycosis fungoides - a pilot study","volume":"15","author":"Chong","year":"2004","journal-title":"Journal of Dermatological Treatment"},{"issue":"5","key":"10.1002\/14651858.CD008946.pub3-BIB0006|cit6","first-page":"581","article-title":"Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma","volume":"137","author":"Duvic","year":"2001","journal-title":"Archives of Dermatology"},{"issue":"2","key":"10.1002\/14651858.CD008946.pub3-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1046\/j.1440-0960.2001.00488.x","article-title":"Bexarotene capsules and gel for previously treated patients with cutaneous T-cell lymphoma: results of the Australian patients treated on phase II trials","volume":"42","author":"Prince","year":"2001","journal-title":"Australasian Journal of Dermatology"},{"issue":"6","key":"10.1002\/14651858.CD008946.pub3-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1067\/mjd.2001.113478","article-title":"A phase III, randomized, double-blind, placebo-controlled study of peldesine (BCX-34) cream as topical therapy for cutaneous T-cell lymphoma","volume":"44","author":"Duvic","year":"2001","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"1","key":"10.1002\/14651858.CD008946.pub3-BIB0009|cit9","first-page":"241","article-title":"Low dose bexarotene (Targretin\u00ae) capsules and phototherapy for early stage cutaneous T-Cell lymphoma","volume":"119","author":"Guitart","year":"2002","journal-title":"Journal of Investigative Dermatology"},{"key":"10.1002\/14651858.CD008946.pub3-BIB0010|cit10","unstructured":"A muliticenter, dose-randomized evaluation of Targretin capsules plus PUVA in patients with stage IB - IIA cutaneous T-Cell lymphoma clinicaltrials.gov\/ct\/show\/NCT00030589"},{"key":"10.1002\/14651858.CD008946.pub3-BIB0011|cit11","first-page":"257","article-title":"Conservative vs. aggressive therapy in mycosis fungoides","volume":"8","author":"Kaye","year":"1989","journal-title":"Proceedings of the American Society of Clinical Oncology"},{"key":"10.1002\/14651858.CD008946.pub3-BIB0012|cit12","first-page":"195","article-title":"A randomized trial comparing conservative and aggressive therapy in mycosis fungoides (MF)","volume":"5","author":"Kaye","year":"1986","journal-title":"Proceedings of the American Society of Clinical Oncology"},{"issue":"26","key":"10.1002\/14651858.CD008946.pub3-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1056\/NEJM198912283212603","article-title":"A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides","volume":"321","author":"Kaye","year":"1989","journal-title":"New England Journal of Medicine"},{"issue":"Supp 1","key":"10.1002\/14651858.CD008946.pub3-BIB0014|cit14","doi-asserted-by":"publisher","first-page":"2901","DOI":"10.1182\/blood-2018-99-118473","article-title":"Long-term clinical benefit to anti-CCR4 mogamulizumab: results from the phase 3 mavoric study in previously treated cutaneous t-cell lymphoma (CTCL)","volume":"132","author":"Bagot","year":"2018","journal-title":"Blood"},{"issue":"S1","key":"10.1002\/14651858.CD008946.pub3-BIB0015|cit15","doi-asserted-by":"publisher","first-page":"77-8","DOI":"10.1111\/bjh.15226","article-title":"Mogamulizumab demonstrates significant improvement in PFS compared to vorinostat in patients with previously treated cutaneous T-cell lymphoma (CTCL)","volume":"181","author":"Cowan","year":"2018","journal-title":"British Journal of Haematology"},{"issue":"9","key":"10.1002\/14651858.CD008946.pub3-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/S1470-2045(18)30379-6","article-title":"Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial","volume":"19","author":"Kim","year":"2018","journal-title":"Lancet Oncology"},{"key":"10.1002\/14651858.CD008946.pub3-BIB0017|cit17","unstructured":"Study of KW-0761 versus vorinostat in relapsed\/refractory CTCL clinicaltrials.gov\/ct2\/show\/NCT01728805"},{"issue":"15","key":"10.1002\/14651858.CD008946.pub3-BIB0018|cit18","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000060","article-title":"Quality of life in cutaneous T-cell lymphoma subjects treated with anti-CCR4 monoclonal antibody mogamulizumab versus vorinostat: results from the phase 3 MAVORIC trial","volume":"36","author":"Porcu","year":"2018","journal-title":"Journal of Clinical Oncology"},{"issue":"S1","key":"10.1002\/14651858.CD008946.pub3-BIB0019|cit19","first-page":"85","article-title":"Quality of life in cutaneous t-cell lymphoma subjects treated with the anti-ccr4 monoclonal antibody mogamulizumab versus vorinostat: results from the phase 3 mavoric trial","volume":"2","author":"Quaglino","year":"2018","journal-title":"Hemasphere"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD008946.pub3-BIB0020|cit20","first-page":"94","article-title":"Efficacy of mogamulizumab by prior systemic therapy in patients with previously treated cutaneous T-cell lymphoma: Post hoc analysis from the phase 3 MAVORIC study","volume":"185","author":"Scarisbrick","year":"2019","journal-title":"British Journal of Haematology"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD008946.pub3-BIB0021|cit21","first-page":"272","article-title":"Quality of life in cutaneous T-cell lymphoma subjects treated with the anti-CCR4 monoclonal antibody mogamulizumab versus vorinostat: Results from the phase 3 MAVORIC trial","volume":"41","author":"Tsianakas","year":"2018","journal-title":"Oncology Research and Treatment"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD008946.pub3-BIB0022|cit22","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1182\/blood-2018-99-114819","article-title":"Efficacy of mogamulizumab by prior systemic therapy in patients with previously treated cutaneous T-cell lymphoma: post hoc analysis from the phase 3 mavoric study","volume":"132","author":"Zinzani","year":"2018","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD008946.pub3-BIB0023|cit23","first-page":"S84","article-title":"Positive results of a pivotal phase ii trial testing a manufactured 0.02% Mechlorethamine gel in mycosis fungoides (mf)","volume":"131","author":"Lessin","year":"2011","journal-title":"Journal of Investigative Dermatology"},{"issue":"1","key":"10.1002\/14651858.CD008946.pub3-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1001\/2013.jamadermatol.541","article-title":"Topical chemotherapy in cutaneous T-cell lymphoma: positive results of a randomized, controlled, multicenter trial testing the efficacy and safety of a novel mechlorethamine, 0.02%, gel in mycosis fungoides","volume":"149","author":"Lessin","year":"2013","journal-title":"JAMA Dermatology"},{"key":"10.1002\/14651858.CD008946.pub3-BIB0025|cit25","unstructured":"Safety and efficacy of nitrogen mustard in treatment of mycosis fungoides clinicaltrials.gov\/ct2\/show\/NCT00168064"},{"issue":"4","key":"10.1002\/14651858.CD008946.pub3-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"222","DOI":"10.3816\/CLM.2002.n.003","article-title":"Quality-of-life improvements in cutaneous T-cell lymphoma patients treated with denileukin diftitox (ONTAK)","volume":"2","author":"Duvic","year":"2002","journal-title":"Clinical Lymphoma"},{"issue":"10 Suppl 1 (Pt","key":"10.1002\/14651858.CD008946.pub3-BIB0027|cit27","first-page":"586a","article-title":"Pivotal phase III trial of two dose levels of DAB389IL-2 (Ontak\u00ae) for the treatment of mycosis fungoides (MF)","volume":"90","author":"Kuzel","year":"1997","journal-title":"Blood"},{"key":"10.1002\/14651858.CD008946.pub3-BIB0028|cit28","unstructured":"Study of ONTAK (Denileukin Diftitox) in cutaneous T-Cell lymphoma (CTCL) patients clinicaltrials.gov\/ct2\/show\/NCT00050999"},{"issue":"2","key":"10.1002\/14651858.CD008946.pub3-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1200\/JCO.2001.19.2.376","article-title":"Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma","volume":"19","author":"Olsen","year":"2001","journal-title":"Journal of Clinical Oncology"},{"issue":"4","key":"10.1002\/14651858.CD008946.pub3-BIB0030|cit30","first-page":"678","article-title":"Pivotal phase III trial of two dose levels of DAB 389 IL-2 (ONTAK) for the treatment of cutaneous T-cell lymphoma (CTCL)","volume":"110","author":"Olsen","year":"1998","journal-title":"Journal of Investigative Dermatology"},{"key":"10.1002\/14651858.CD008946.pub3-BIB0031|cit31","doi-asserted-by":"crossref","unstructured":"Horwitz S Whittaker S Duvic M Dummer R Kim YH Scarisbrick J Response by stage in CD30-positive (CD30+) cutaneous T cell lymphoma (CTCL) patients receiving brentuximab vedotin (BV) vs physician's choice (PC) in the phase 3 ALCANZA study Hematological oncology. Conference: 14th international conference on malignant lymphoma palazzo dei congressi. Switzerland 2017 245-7 10.1002\/hon.2438","DOI":"10.1002\/hon.2438_109"},{"issue":"10094","key":"10.1002\/14651858.CD008946.pub3-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/S0140-6736(17)31266-7","article-title":"Brentuximab vedotin or physician\u2019s choice in CD30-positivecutaneous T-cell lymphoma (ALCANZA): an international,open-label, randomised, phase 3, multicentre trial","volume":"390","author":"Horwitz","year":"2017","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD008946.pub3-BIB0033|cit33","unstructured":"Horwitz SM Scarisbrick JJ Dummer R Duvic M Kim YH Walewski J Updated analyses of the international, open-label, randomized, phase 3 alcanza study: longer-term evidence for superiority of brentuximab vedotin versus methotrexate or bexarotene for CD30-positive cutaneous T-cell lymphoma (CTCL) Blood. Conference: 59th annual meeting of the american society of hematology, ASH 2017. United states 2017"},{"key":"10.1002\/14651858.CD008946.pub3-BIB0034|cit34","doi-asserted-by":"crossref","unstructured":"Kim YH Prince HM Whittaker S Horwitz SM Duvic M Scarisbrick J Brentuximab vedotin vs physician's choice in CTCL patients from the phase 3 ALCANZA study: analysis of outcomes by CD30 expression Hematological Oncology. Conference: 14th international conference on malignant lymphoma palazzo dei congressi. Switzerland 2017 77-8 10.1002\/hon.2437","DOI":"10.1002\/hon.2437_65"},{"issue":"15 Supplement 1","key":"10.1002\/14651858.CD008946.pub3-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"7517","DOI":"10.1200\/JCO.2017.35.15_suppl.7517","article-title":"Outcomes by CD30 expression in patients with CTCL receiving brentuximab vedotin (BV) vs physician's choice (PC) in the Phase 3 ALCANZA study","volume":"35","author":"Kim","year":"2017","journal-title":"Journal of Clinical Oncology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD008946.pub3-BIB0036|cit36","first-page":"278","article-title":"Phase 3 study of brentuximab vedotin versus physician's choice of methotrexate or bexarotene in patients (PTS) with CD30-positive (CD30+) cutaneous T-cell lymphoma (CTCL). The alcanza study","volume":"31","author":"Kim","year":"2013","journal-title":"Hematological Oncology"},{"issue":"5 Suppl 1","key":"10.1002\/14651858.CD008946.pub3-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"S45","DOI":"10.1016\/j.jid.2017.02.278","article-title":"Brentuximab vedotin demonstrates superior activity to standard therapy in CD30-expressing (CD30+) cutaneous T-cell lymphoma (CTCL) in the randomized phase 3 ALCANZA study","volume":"137","author":"Kim","year":"2017","journal-title":"Journal of Investigative Dermatology"},{"key":"10.1002\/14651858.CD008946.pub3-BIB0038|cit38","doi-asserted-by":"crossref","unstructured":"Kim YH Whittaker S Horwitz SM Duvic M Dummer R Scarisbrick JJ Brentuximab vedotin demonstrates significantly superior clinical outcomes in patients with CD30-expressing cutaneous T cell lymphoma versus physician's choice (Methotrexate or Bexarotene): the phase 3 alcanza study Blood. Conference: 58th annual meeting of the american society of hematology, ASH 2016. United states. Conference start: 20161203. Conference end: 20161206 2016","DOI":"10.1182\/blood.V128.22.182.182"},{"key":"10.1002\/14651858.CD008946.pub3-BIB0039|cit39","unstructured":"A randomised, open-label, phase 3 trial of brentuximab vedotin (SGN-35) versus physician's choice (methotrexate or bexarotene) in patients with CD30-positive cutaneous T-cell lymphoma clinicaltrials.gov\/ct2\/show\/NCT01578499"},{"key":"10.1002\/14651858.CD008946.pub3-BIB0040|cit40","doi-asserted-by":"crossref","unstructured":"Prince HM Dummer R Whittaker S Horwitz S Duvic M Scarisbrick J Patient-reported outcomes and quality of life in patients with cutaneous T cell lymphoma: results from the phase 3 ALCANZA study Hematological Oncology. Conference: 14th international conference on malignant lymphoma palazzo dei congressi. Switzerland 2017 247-8 10.1002\/hon.2438","DOI":"10.1002\/hon.2438_110"},{"key":"10.1002\/14651858.CD008946.pub3-BIB0041|cit41","unstructured":"Zagadailov E Prince HM Whittaker S Horwitz S Duvic M Kim Y Phase 3 alcanza study of brentuximab vedotin (BV) or physician's choice (PC) of methotrexate (MTX) or bexarotene (BEX) in CD30-positive cutaneous T-cell lymphoma (CTCL): number needed to treat analysis Haematologica. Conference: 22th congress of the european hematology association. Spain 2017 251"},{"issue":"6","key":"10.1002\/14651858.CD008946.pub3-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/j.jaad.2010.02.039","article-title":"A phase II placebo-controlled study of photodynamic therapy with topical hypericin and visible light irradiation in the treatment of cutaneous T-cell lymphoma and psoriasis","volume":"63","author":"Rook","year":"2010","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"Suppl","key":"10.1002\/14651858.CD008946.pub3-BIB0043|cit43","first-page":"S97","article-title":"Treatment of cutaneous T-cell lymphoma with Interferon alpha and PUVA versus Interferon alpha and Acitretin - results of a prospective randomised multi-centre study","volume":"48","author":"Otte","year":"1997","journal-title":"Der Hautarzt"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD008946.pub3-BIB0044|cit44","first-page":"66","article-title":"Open controlled clinical trial on the use of interferon plus acitretin versus interferon plus PUVA in patients with cutaneous T-cell lymphoma (CTCL)","volume":"7","author":"Otte","year":"1996","journal-title":"Annals of Oncology"},{"issue":"10","key":"10.1002\/14651858.CD008946.pub3-BIB0045|cit45","first-page":"3578","article-title":"Prospective randomized multicenter clinical trial on the use of interferon -2a plus acitretin versus interferon -2a plus PUVA in patients with cutaneous T-cell lymphoma stages I and II","volume":"92","author":"Stadler","year":"1998","journal-title":"Blood"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD008946.pub3-BIB0046|cit46","first-page":"S268","article-title":"Therapy of cutaneous T-cell lymphoma with PUVA versus interferon alfa plus PUVA: first results","volume":"12","author":"Bohmeyer","year":"1999","journal-title":"Journal of the European Academy of Dermatology & Venereology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD008946.pub3-BIB0047|cit47","first-page":"S55","article-title":"Prospective randomized multicentre therapy optimizing protocol for therapy of cutaneous t-cell-lymphoma with PUVA versus Interferon \u03b1 + PUVA","volume":"76","author":"Bohmeyer","year":"2001","journal-title":"Zeitschrift f\u00fcr Hautkrankheiten"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD008946.pub3-BIB0048|cit48","first-page":"S99","article-title":"Prospective randomized multicentre therapy optimizing protocol for therapy of cutaneous t-cell-lymphoma with PUVA versus Interferon \u03b1 + PUVA","volume":"1","author":"Kremer","year":"2003","journal-title":"Journal der Deutschen Dermatologischen Gesellschaft"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD008946.pub3-BIB0049|cit49","first-page":"S2","article-title":"Therapy of cutaneous t-cell-lymphoma with PUVA versus Interferon \u03b1 plus PUVA: first results of a prospective randomized multicentre therapy optimizing protocol","volume":"50","author":"Otte","year":"1999","journal-title":"Der Hautarzt"},{"issue":"Suppl","key":"10.1002\/14651858.CD008946.pub3-BIB0050|cit50","first-page":"P2.03.08","article-title":"Combination therapy of cutaneous t-cell-lymphoma with interferon alfa 2a and PUVA","volume":"162","author":"Otte","year":"1993","journal-title":"Zentralblatt Haut- und Geschlechtskrankheiten"},{"issue":"18S Pt 1","key":"10.1002\/14651858.CD008946.pub3-BIB0051|cit51","first-page":"432","article-title":"Prospective, randomized, multicentre clinical trial on the use of interferon a 2a plus PUVA versus PUVA monotherapy in patients with cutaneous T-cell lymphoma, stages I and II [Abstract 7541]. ASCO annual meeting proceedings","volume":"24","author":"Stadler","year":"2006","journal-title":"Journal of Clinical Oncology"},{"issue":"1","key":"10.1002\/14651858.CD008946.pub3-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"47","DOI":"10.2340\/00015555624753","article-title":"Transfer factor therapy in mycosis fungoides: a double-blind study","volume":"62","author":"Thestrup-Pedersen","year":"1982","journal-title":"Acta Dermato-Venereologica"},{"key":"10.1002\/14651858.CD008946.pub3-BIB0053|cit53","unstructured":"A multi-center, randomized study on oral 8-methoxypsoralen plus UVA with or without maintenance therapy in mycosis fungoides EORTC\/ISCL stage IA to IIB clinicaltrials.gov\/ct2\/show\/NCT01686594"},{"issue":"5","key":"10.1002\/14651858.CD008946.pub3-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1001\/jamadermatol.2018.5905","article-title":"Evaluation of low-dose, low-frequency oral psoralen-UV-A treatment with or without maintenance on early-stage mycosis fungoides: A randomized clinical trial","volume":"155","author":"Vieyra-Garcia","year":"2019","journal-title":"JAMA Dermatology"},{"issue":"6","key":"10.1002\/14651858.CD008946.pub3-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1001\/archderm.1987.01660300079016","article-title":"Recombinant interferon alfa-2b in plaque-phase mycosis fungoides. Intralesional and low-dose intramuscular therapy","volume":"123","author":"Vonderheid","year":"1987","journal-title":"Archives of Dermatology"},{"key":"10.1002\/14651858.CD008946.pub3-BIB0056|cit56","unstructured":"Ultraviolet light therapy using methoxsalen with or without Bexarotene in treating patients with mycosis fungoides clinicaltrials.gov\/ct2\/show\/NCT00056056"},{"issue":"3","key":"10.1002\/14651858.CD008946.pub3-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1111\/j.1365-2133.2012.11156.x","article-title":"Efficacy and safety of bexarotene combined with psoralen-ultraviolet A (PUVA) compared with PUVA treatment alone in stage IB-IIA mycosis fungoides: final results from the EORTC Cutaneous Lymphoma Task Force phase III randomized clinical trial 21011 (NCT00056056)","volume":"167","author":"Whittaker","year":"2012","journal-title":"British Journal of Dermatology"},{"issue":"15 Suppl 1","key":"10.1002\/14651858.CD008946.pub3-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"8076","DOI":"10.1200\/jco.2012.30.15_suppl.8076","article-title":"Efficacy and safety of bexarotene combined with psoralen\/ultraviolet A light (PUVA) compared to PUVA treatment alone in stage IB-IIa mycosis fungoides (MF): Final results from EORTC cutaneous lymphoma task force (CLTF) phase III clinical trial 21011","volume":"30","author":"Whittaker","year":"2012","journal-title":"Journal of Clinical Oncology"},{"issue":"4","key":"10.1002\/14651858.CD008946.pub3-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/S0190-9622(85)70205-8","article-title":"Intralesional interferon in the treatment of early mycosis fungoides","volume":"13","author":"Wolff","year":"1985","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"1","key":"10.1002\/14651858.CD008946.pub3-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1111\/j.1365-2133.2008.08886.x","article-title":"Psoralen plus ultraviolet A +\/- interferon-alpha treatment resistance in mycosis fungoides: the role of tumour microenvironment, nuclear transcription factor-kappaB and T-cell receptor pathways","volume":"160","author":"Wozniak","year":"2008","journal-title":"British Journal of Dermatology"},{"issue":"1","key":"10.1002\/14651858.CD008946.pub3-BIB0061|cit61","first-page":"49","article-title":"Comparison of the use of teniposide and vincristine in combination chemotherapy for non-Hodgkin's lymphoma","volume":"66","year":"1982","journal-title":"Cancer Treatment Reports"},{"issue":"1075","key":"10.1002\/14651858.CD008946.pub3-BIB0062|cit62","first-page":"31","article-title":"Bexarotene (Targretin) for cutaneous T-cell lymphoma","volume":"42","year":"2000","journal-title":"Medical Letter on Drugs and Therapeutics"},{"issue":"4","key":"10.1002\/14651858.CD008946.pub3-BIB0063|cit63","first-page":"619","article-title":"Preliminary evaluation of 15 chemotherapeutic agents applied topically in the treatment of mycosis fungoides","volume":"63","author":"Argyropoulos","year":"1979","journal-title":"Cancer Treatment Reports"},{"issue":"9","key":"10.1002\/14651858.CD008946.pub3-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"538-42","DOI":"10.1179\/1607845415Y.0000000002","article-title":"Interferon and low doses of methotrexate versus interferon and retinoids in the treatment of refractory\/relapsed cutaneous T-cell lymphoma","volume":"20","author":"Aviles","year":"2015","journal-title":"Hematology"},{"key":"10.1002\/14651858.CD008946.pub3-BIB0065|cit65","first-page":"1137","article-title":"Not available","volume":"11","author":"Bazex","year":"1975","journal-title":"Revue de Medecine de Toulouse"},{"issue":"6 Pt 1","key":"10.1002\/14651858.CD008946.pub3-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/0190-9622(91)70307-N","article-title":"Topical mechlorethamine in the treatment of mycosis fungoides. Uniformity of application and potential for environmental contamination","volume":"25","author":"Breneman","year":"1991","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"4","key":"10.1002\/14651858.CD008946.pub3-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1200\/JCO.1994.12.4.769","article-title":"Randomized comparison of MACOP-B with CHOP in patients with intermediate-grade non-Hodgkin's lymphoma. The Australian and New Zealand Lymphoma Group","volume":"12","author":"Cooper","year":"1994","journal-title":"Journal of Clinical Oncology"},{"issue":"8-9","key":"10.1002\/14651858.CD008946.pub3-BIB0068|cit68","first-page":"951","article-title":"Phase I trial of metoprine in patients with advanced cancer","volume":"64","author":"Currie","year":"1980","journal-title":"Cancer Treatment Reports"},{"issue":"3","key":"10.1002\/14651858.CD008946.pub3-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1111\/j.1365-2141.2006.06457.x","article-title":"Phase II study of denileukin diftitox for relapsed\/refractory B-Cell non-Hodgkin's lymphoma","volume":"136","author":"Dang","year":"2007","journal-title":"British Journal of Haematology"},{"issue":"3","key":"10.1002\/14651858.CD008946.pub3-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1111\/j.1749-6632.1958.tb42654.x","article-title":"Clinical evaluation of CB 1348 in leukemias and lymphomas","volume":"68","author":"Doan","year":"1958","journal-title":"Annals of the New York Academy of Sciences"},{"issue":"19","key":"10.1002\/14651858.CD008946.pub3-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"4541","DOI":"10.1002\/cncr.25377","article-title":"Interim report of a phase 2 clinical trial of lenalidomide for T-cell non-Hodgkin lymphoma","volume":"116","author":"Dueck","year":"2010","journal-title":"Cancer"},{"issue":"21","key":"10.1002\/14651858.CD008946.pub3-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1182\/blood.V116.21.2863.2863","article-title":"Efficacy of denileukin diftitox retreatment in patients with cutaneous T-cell lymphoma who relapsed after initial response","volume":"116","author":"Duvic","year":"2010","journal-title":"Blood"},{"key":"10.1002\/14651858.CD008946.pub3-BIB0073|cit73","doi-asserted-by":"publisher","first-page":"e85","DOI":"10.1097\/01.cmr.0000382933.41435.dc","article-title":"Broadband UVA versus PUVA in the treatment of early stage mycosis fungoides: a comparative study","volume":"20","author":"Fawzi","year":"2010","journal-title":"Melanoma Research"},{"issue":"14","key":"10.1002\/14651858.CD008946.pub3-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1056\/NEJM199304083281404","article-title":"Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma","volume":"328","author":"Fisher","year":"1993","journal-title":"New England Journal of Medicine"},{"issue":"7","key":"10.1002\/14651858.CD008946.pub3-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1002\/ajh.22039","article-title":"Predictors of complete responses with denileukin diftitox in cutaneous T-cell lymphoma","volume":"86","author":"Foss","year":"2011","journal-title":"American Journal of Hematology"},{"issue":"1","key":"10.1002\/14651858.CD008946.pub3-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"59-63","DOI":"10.2340\/00015555595963","article-title":"Tumour stage of mycosis fungoides treated with bleomycin and methotrexate: report from the Scandinavian mycosis fungoides study group","volume":"59","author":"Groth","year":"1979","journal-title":"Acta Dermato-Venereologica"},{"issue":"5","key":"10.1002\/14651858.CD008946.pub3-BIB0077|cit77","doi-asserted-by":"publisher","first-page":"801-15","DOI":"10.1067\/S0190-9622(3)01475-0","article-title":"Topical bexarotene therapy for patients with refractory or persistent early-stage cutaneous T-cell lymphoma: Results of the phase III clinical trial","volume":"49","author":"Heald","year":"2003","journal-title":"Journal of the American Academy of Dermatology"},{"key":"10.1002\/14651858.CD008946.pub3-BIB0078|cit78","unstructured":"Post-marketing clinical study of Ogamma 100 in patients with mycosis fungoides www.clinicaltrials.jp\/user\/showCteDetailE.jsp?japicId=JapicCTI-050041"},{"issue":"6","key":"10.1002\/14651858.CD008946.pub3-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1002\/1097-0142(196906)23:6<1280::AID-CNCR2820230606>3.0.CO;2-U","article-title":"Comparison of chlorambucil and streptonigrin (NSC-45383) in the treatment of malignant lymphomas","volume":"23","author":"Kaung","year":"1969","journal-title":"Cancer"},{"issue":"1","key":"10.1002\/14651858.CD008946.pub3-BIB0080|cit80","first-page":"1185","article-title":"PUVA vs. PUVA and interferon alpha for treatment of mycosis fungoides","volume":"121","author":"Kujawska","year":"2003","journal-title":"Journal of Investigative Dermatology"},{"issue":"15 Suppl","key":"10.1002\/14651858.CD008946.pub3-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"e18509","DOI":"10.1200\/jco.2010.28.15_suppl.e18509","article-title":"Correlates of capillary leak syndrome (CLS) in patients with cutaneous T-cell lymphoma (CTCL) during treatment with denileukin diftitox (DD) in a placebo (PBO)-controlled phase III trial","volume":"28","author":"Kuzel","year":"2010","journal-title":"Journal of Clinical Oncology"},{"issue":"6-7","key":"10.1002\/14651858.CD008946.pub3-BIB0082|cit82","first-page":"541-7","article-title":"Mycosis fungoides and radiotherapy. Value of combined total skin electron therapy and whole-body photon therapy","volume":"113","author":"Lambert","year":"1986","journal-title":"Annales de Dermatologie et de Venereologie"},{"key":"10.1002\/14651858.CD008946.pub3-BIB0083|cit83","doi-asserted-by":"crossref","unstructured":"Lansigan F Foss FM Rate of infection and immunosuppression in two phase III studies of denileukin diftitox (DD) in cutaneous T-cell lymphoma (CTCL) Journal of Clinical Oncology 2010 28 15 Suppl e18515","DOI":"10.1200\/jco.2010.28.15_suppl.e18515"},{"issue":"4","key":"10.1002\/14651858.CD008946.pub3-BIB0084|cit84","first-page":"3896","article-title":"13-Cis retinoic acid as treatment for mycosis fungoides: Clinical results of a phase II trial","volume":"43","author":"Loescher","year":"1984","journal-title":"Federation Proceedings"},{"issue":"9","key":"10.1002\/14651858.CD008946.pub3-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1111\/j.1365-2133.1968.tb12362.x","article-title":"Fluocinolone acetonide 0.2 per cent cream--a co-operative clinical trial","volume":"80","author":"Marsden","year":"1968","journal-title":"British Journal of Dermatology"},{"issue":"1","key":"10.1002\/14651858.CD008946.pub3-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1159\/000112814","article-title":"Therapeutic apheresis - Many ways to go","volume":"35","author":"Moog","year":"2008","journal-title":"Transfusion Medicine and Hemotherapy"},{"key":"10.1002\/14651858.CD008946.pub3-BIB0087|cit87","unstructured":"Photodynamic therapy in treating patients with lymphoma or chronic lymphocytic leukemia clinicaltrials.gov\/ct2\/show\/NCT00054171"},{"key":"10.1002\/14651858.CD008946.pub3-BIB0088|cit88","unstructured":"A phase I\/II open label, multi-center study for the evaluation of Pf-3512676 (CPG 7909) in patients with stage Ib to Iva cutaneous T-Cell lymphoma clinicaltrials.gov\/ct2\/show\/NCT00091208"},{"key":"10.1002\/14651858.CD008946.pub3-BIB0089|cit89","unstructured":"Study evaluating two dose levels of Targretin capsules in patients with refractory cutaneous T-cell lymphoma (CTCL) clinicaltrials.gov\/ct2\/show\/NCT01007448"},{"key":"10.1002\/14651858.CD008946.pub3-BIB0090|cit90","unstructured":"Low-dose (12 Gy) TSEBT+Vorinostat versus low-dose TSEBT monotherapy in mycosis fungoides clinicaltrials.gov\/ct2\/show\/NCT01187446"},{"key":"10.1002\/14651858.CD008946.pub3-BIB0091|cit91","unstructured":"Vorinostat with or without Bortezomib in treating patients with refractory or recurrent stage IIB, stage III, or stage IV cutaneous T-Cell lymphoma clinicaltrials.gov\/ct2\/show\/NCT01386398"},{"key":"10.1002\/14651858.CD008946.pub3-BIB0092|cit92","unstructured":"Effect of Neurokinin-1 Receptor (NK1R) antagonism on pruritus in patients with Sezary syndrome clinicaltrials.gov\/ct2\/show\/NCT01625455"},{"issue":"6","key":"10.1002\/14651858.CD008946.pub3-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1159\/000252071","article-title":"Treatment of localized skin lesions with betamethasone 17-valerate and triamcinolone acetonide in alcoholic solution under occlusive dressing. A double blind comparative study","volume":"145","author":"Neering","year":"1972","journal-title":"Dermatologica"},{"issue":"18 Suppl","key":"10.1002\/14651858.CD008946.pub3-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"8026","DOI":"10.1200\/jco.2007.25.18_suppl.8026","article-title":"Efficacy and safety of denileukin diftitox (Dd) in a phase III, double-blind, placebo-controlled study of CD25+ patients with cutaneous T-cell lymphoma (CTCL)","volume":"25","author":"Negro-Vilar","year":"2007","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD008946.pub3-BIB0095|cit95","doi-asserted-by":"crossref","unstructured":"O'Neill B Geskin L Story S Novel combination therapy for the treatment of cutaneous T-cell lymphoma Journal of the American Academy of Dermatology 2013 68 4 Suppl 1 AB147","DOI":"10.1016\/j.jaad.2012.12.611"},{"issue":"4","key":"10.1002\/14651858.CD008946.pub3-BIB0096|cit96","first-page":"498","article-title":"Interferon alfa-2A in the treatment of cutaneous T cell lymphoma","volume":"86","author":"Olsen","year":"1986","journal-title":"Journal of Investigative Dermatology"},{"key":"10.1002\/14651858.CD008946.pub3-BIB0097|cit97","doi-asserted-by":"crossref","unstructured":"Pan Y Prince HM Ellis L Culver K LBH589, a novel deacetylase inhibitor (DACi), in the treatment of cutaneous T-cell lymphoma (CTCL): changes in tumor gene expression profiles related to clinical response after therapy 11th World Congress on Cancers of the Skin. 2007 June 8-11. Amsterdam, The Netherlands 2007 Abstract 00172","DOI":"10.1182\/blood.V108.11.2715.2715"},{"issue":"4","key":"10.1002\/14651858.CD008946.pub3-BIB0098|cit98","first-page":"563","article-title":"Clinical efficacy of a novel purine nucleoside phosphorylase inhibitor (BCX-34) in the treatment of cutaneous T-cell lymphoma","volume":"104","author":"Peugeot","year":"1995","journal-title":"Journal of Investigative Dermatology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD008946.pub3-BIB0099|cit99","first-page":"S96","article-title":"UVA1-Phototherapie versus PUVA-Photochemotherapie in der Behandlung von Patienten mit kutanem T-Zell-Lymphom (CTCL)","volume":"76","author":"Plettenberg","year":"2001","journal-title":"Zeitschrift f\u00fcr Hautkrankheiten"},{"issue":"11","key":"10.1002\/14651858.CD008946.pub3-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1200\/JCO.2009.26.2386","article-title":"Phase III placebo-controlled trial of denileukin diftitox for patients with cutaneous T-cell lymphoma","volume":"28","author":"Prince","year":"2010","journal-title":"Journal of Clinical Oncology"},{"issue":"Suppl","key":"10.1002\/14651858.CD008946.pub3-BIB0101|cit101","first-page":"S96","article-title":"Extracorporal photophoresis (ECP) + Interferon-alpha 2a vs. ECP in patients with cutaneous T-cell lymphoma. Evaluation using a new score (CTCL-SI)","volume":"48","author":"Dippel","year":"1997","journal-title":"Der Hautarzt"},{"key":"10.1002\/14651858.CD008946.pub3-BIB0102|cit102","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1159\/000418097","article-title":"Combination of retinoids and PUVA (Re-PUVA) in the treatment of cutaneous T cell lymphomas","volume":"19","author":"Serri","year":"1990","journal-title":"Current Problems in Dermatology"},{"issue":"23","key":"10.1002\/14651858.CD008946.pub3-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1182\/blood.V126.23.1513.1513","article-title":"Phase II study of chidamide, a new subtype-selective oral histone deacetylase inhibitor, in patients with relapsed or refractory cutaneous T-cell lymphoma","volume":"126","author":"Shi","year":"2015","journal-title":"Blood"},{"issue":"2","key":"10.1002\/14651858.CD008946.pub3-BIB0104|cit104","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/j.1365-2141.2010.08329.x","article-title":"Upfront VIP-reinforced-ABVD (VIP-rABVD) is not superior to CHOP\/21 in newly diagnosed peripheral T cell lymphoma. Results of the randomized phase III trial GOELAMS-LTP95","volume":"151","author":"Simon","year":"2010","journal-title":"British Journal of Haematology"},{"issue":"2","key":"10.1002\/14651858.CD008946.pub3-BIB0105|cit105","first-page":"287","article-title":"Scandinavian mycosis fungoides study group","volume":"64","author":"Thomsen","year":"1977","journal-title":"Bulletin du Cancer"},{"issue":"4","key":"10.1002\/14651858.CD008946.pub3-BIB0106|cit106","first-page":"709-11","article-title":"Scandinavian mycosis fungoides trial","volume":"63","author":"Thomsen","year":"1979","journal-title":"Cancer Treatment Reports"},{"issue":"6","key":"10.1002\/14651858.CD008946.pub3-BIB0107|cit107","first-page":"536","article-title":"Retinoids plus PUVA (RePUVA) and PUVA in mycosis fungoides, plaque stage","volume":"69","author":"Thomsen","year":"1989","journal-title":"Acta Dermato-Venereologica"},{"issue":"6","key":"10.1002\/14651858.CD008946.pub3-BIB0108|cit108","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1159\/000250866","article-title":"Topical chemotherapy in mycosis fungoides","volume":"157","author":"Touraine","year":"1978","journal-title":"Dermatologica"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD008946.pub3-BIB0109|cit109","first-page":"10","article-title":"A randomized, open, crossover study to compare the efficacy of extracorporeal photopheresis with methotrexate in the treatment of erythrodermic primary cutaneous T-cell lymphoma","volume":"153","author":"Wain","year":"2005","journal-title":"British Journal of Dermatology"},{"issue":"5-6","key":"10.1002\/14651858.CD008946.pub3-BIB0110|cit110","doi-asserted-by":"crossref","first-page":"601","DOI":"10.3109\/10428199809057572","article-title":"Phase II study of mitoguazone, cyclophosphamide, doxorubicin, vincristine and prednisone for patients with diffuse histologic subtypes of non-Hodgkin's lymphoma: an Eastern Cooperative Oncology Group Study (PE481)","volume":"30","author":"Wiernik","year":"1998","journal-title":"Leukemia & Lymphoma"},{"issue":"4","key":"10.1002\/14651858.CD008946.pub3-BIB0111|cit111","doi-asserted-by":"crossref","first-page":"987-95","DOI":"10.1016\/0360-3016(95)00073-8","article-title":"Systemic chemotherapy and extracorporeal photochemotherapy for T3 and T4 cutaneous T-cell lymphoma patients who have achieved a complete response to total skin electron beam therapy","volume":"32","author":"Wilson","year":"1995","journal-title":"International Journal of Radiation Oncology, Biology, Physics"},{"issue":"1","key":"10.1002\/14651858.CD008946.pub3-BIB0112|cit112","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/0021-9681(60)90137-5","article-title":"Appraisal of methods for the study of chemotherapy of cancer in man: Comparative therapeutic trial of nitrogen mustard and triethylene thiophosphoramide","volume":"11","author":"Zubrod","year":"1960","journal-title":"Journal of Chronic Diseases"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD008946.pub3-BIB0113|cit113","first-page":"S104","article-title":"A multicenter, open-label, randomized, phase I\/II study evaluating the safety and efficacy of low-dose (12 Gy) total skin electron beam therapy (TSEBT) combined with vorinostat versus low-dose TSEBT monotherapy in patients with mycosis fungoides","volume":"134","author":"Bashey","year":"2014","journal-title":"Journal of Investigative Dermatology"},{"issue":"15 Suppl","key":"10.1002\/14651858.CD008946.pub3-BIB0114|cit114","doi-asserted-by":"crossref","first-page":"8525","DOI":"10.1200\/jco.2014.32.15_suppl.8525","article-title":"A phase 1b study in cutaneous T-cell lymphoma (CTCL) with the novel topically applied skin-restricted histone deacteylase inhibitor (HDAC-i) SHP-141","volume":"32","author":"Kim","year":"2014","journal-title":"Journal of Clinical Oncology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD008946.pub3-BIB0115|cit115","first-page":"S93","article-title":"Tolerability and encouraging clinical activity of SHP-141, a topical skin-restricted HDAC inhibitor, in a phase 1B study in cutaneous t-cell lymphoma","volume":"134","author":"Kim","year":"2014","journal-title":"Journal of Investigative Dermatology"},{"key":"10.1002\/14651858.CD008946.pub3-BIB0116|cit116","unstructured":"Safety, pharmacodynamics (PD), pharmacokinetics (PK) study of SHP141 in 1A, 1B, or 2A cutaneous T-cell lymphoma (CTCL) clinicaltrials.gov\/ct\/show\/NCT01433731"},{"key":"10.1002\/14651858.CD008946.pub3-BIB0117|cit117","unstructured":"Dose-escalation trial of carfilzomib with and without Romidepsin in cutaneous T-cell lymphoma clinicaltrials.gov\/ct2\/show\/NCT01738594"},{"issue":"15 Suppl","key":"10.1002\/14651858.CD008946.pub3-BIB0118|cit118","doi-asserted-by":"publisher","first-page":"7562","DOI":"10.1200\/JCO.2016.34","article-title":"A phase 2 randomized study of SHAPE Gel (SHP-141) in patients with early-stage cutaneous T-cell lymphoma: Interim results","volume":"34","author":"Duvic","year":"2016","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD008946.pub3-BIB0119|cit119","unstructured":"Efficacy, safety and tolerability study of SHAPE in IA, IB or IIA cutaneous T-cell lymphoma clinicaltrials.gov\/ct2\/show\/NCT02213861"},{"key":"10.1002\/14651858.CD008946.pub3-BIB0120|cit120","unstructured":"Effectiveness of imiquimod topical cream in early stage cutaneous T-cell lymphoma (CTCL) clinicaltrials.gov\/ct2\/show\/NCT02301494"},{"key":"10.1002\/14651858.CD008946.pub3-BIB0121|cit121","unstructured":"Comparison of methotrexate versus interferon-alfa 2b in patients with primary cutaneous T-cell lymphomas clinicaltrials.gov\/ct2\/show\/NCT02323659"},{"key":"10.1002\/14651858.CD008946.pub3-BIB0122|cit122","unstructured":"FLASH [Fluorescent Light Activated Synthetic Hypericin] clinical study: topical SGX301 (synthetic hypericin) for the treatment of cutaneous T-cell lymphoma (mycosis fungoides) clinicaltrials.gov\/ct2\/show\/NCT02448381"},{"key":"10.1002\/14651858.CD008946.pub3-BIB0123|cit123","unstructured":"Naloxone hydrochloride study for relief of pruritus in patients with MF or SS forms of CTCL clinicaltrials.gov\/ct2\/show\/NCT02811783"},{"key":"10.1002\/14651858.CD008946.pub3-BIB0124|cit124","unstructured":"Safety and effectiveness of A-dmDT390-bisFv(UCHT1) fusion protein in subjects with mycosis fungoides (Resimmune\u00ae) clinicaltrials.gov\/ct2\/show\/NCT02943642"},{"key":"10.1002\/14651858.CD008946.pub3-BIB0125|cit125","unstructured":"Resminostat for maintenance treatment of patients with advanced stage mycosis fungoides (MF) or S\u00e9zary syndrome (SS) (RESMAIN) clinicaltrials.gov\/ct2\/show\/NCT02953301"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD008946.pub3-BIB0126|cit126","first-page":"50","article-title":"A multicentre, double blind, randomised, placebo controlled, Phase II trial to evaluate Resminostat for maintenance treatment of patients with advanced stage (Stage IIB-IVB) mycosis fungoides (MF) or Sezary Syndrome (SS) that have achieved disease control with systemic therapy-the RESMAIN Study","volume":"31","author":"Stadler","year":"2017","journal-title":"Journal of the European Academy of Dermatology and Venereology"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD008946.pub3-BIB0127|cit127","doi-asserted-by":"publisher","first-page":"74-5","DOI":"10.1111\/ddg.13300","article-title":"A multicentre, double blind, randomised, placebo-controlled, Phase II trial to evaluate Resminostat for maintenance treatment of patients with advanced stage (Stage IIB-IVB) mycosis fungoides (MF) or Sezary Syndrome (SS) that have achieved disease control with systemic therapy: The RESMAIN Study","volume":"15","author":"Stadler","year":"2017","journal-title":"Journal der Deutschen Dermatologischen Gesellschaft [Journal of the German Society of Dermatology]"},{"key":"10.1002\/14651858.CD008946.pub3-BIB0128|cit128","unstructured":"Durvalumab with or without lenalidomide in treating patients with relapsed or refractory cutaneous or peripheral T cell lymphoma clinicaltrials.gov\/ct2\/show\/NCT03011814"},{"key":"10.1002\/14651858.CD008946.pub3-BIB0129|cit129","unstructured":"A safety, efficacy and pharmacokinetics study of CD11301 for the treatment of cutaneous T-cell lymphoma (CTCL) (CTCL) clinicaltrials.gov\/ct2\/show\/NCT03292406"},{"key":"10.1002\/14651858.CD008946.pub3-BIB0130|cit130","unstructured":"Efficacy of doxycycline in the treatment of early stages of mycosis fungoides: A randomized controlled trial clinicaltrials.gov\/ct2\/show\/NCT03454945"},{"key":"10.1002\/14651858.CD008946.pub3-BIB0131|cit131","unstructured":"SOLAR: A phase 2, randomized, open-label, parallel-group, active comparator, multi-center study to investigate the efficacy and safety of cobomarsen (MRG-106) in subjects with cutaneous T-cell lymphoma (CTCL), mycosis fungoides (MF) subtype clinicaltrials.gov\/ct2\/show\/NCT03713320"},{"key":"10.1002\/14651858.CD008946.pub3-BIB0132|cit132","unstructured":"Efficacy and safety of Targretin capsule 75-mg alone or in combination with phototherapy in Japanese patients with cutaneous T-cell lymphomas upload.umin.ac.jp\/cgi-open-bin\/ctr_e\/ctr_view.cgi?recptno=R000033748"},{"issue":"6","key":"10.1002\/14651858.CD008946.pub3-BIB0133|cit133","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1111\/j.1365-2133.2009.09037.x","article-title":"Bexarotene therapy for mycosis fungoides and S\u00e9zary syndrome","volume":"160","author":"Abbott","year":"2009","journal-title":"British Journal of Dermatology"},{"issue":"31","key":"10.1002\/14651858.CD008946.pub3-BIB0134|cit134","doi-asserted-by":"crossref","first-page":"4730","DOI":"10.1200\/JCO.2009.27.7665","article-title":"Survival outcomes and prognostic factors in mycosis fungoides\/Sezary syndrome: validation of the revised International Society for Cutaneous Lymphomas\/European Organisation for Research and Treatment of Cancer staging proposal","volume":"28","author":"Agar","year":"2010","journal-title":"Journal of Clinical Oncology"},{"issue":"7","key":"10.1002\/14651858.CD008946.pub3-BIB0135|cit135","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1002\/(SICI)1097-0142(19991001)86:7<1368::AID-CNCR37>3.0.CO;2-8","article-title":"Chemotherapy with etoposide, vincristine, doxorubicin, bolus cyclophosphamide, and oral prednisone in patients with refractory cutaneous T-cell lymphoma","volume":"86","author":"Akpek","year":"1999","journal-title":"Cancer"},{"issue":"6","key":"10.1002\/14651858.CD008946.pub3-BIB0136|cit136","doi-asserted-by":"crossref","first-page":"529","DOI":"10.2340\/0001555562529531","article-title":"Transient lymphomatoid papulosis in mycosis fungoides","volume":"62","author":"Aronsson","year":"1982","journal-title":"Acta Dermato-Venereologica"},{"issue":"7","key":"10.1002\/14651858.CD008946.pub3-BIB0137|cit137","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1002\/ajh.21180","article-title":"Lethal vascular leak syndrome after denileukin diftitox administration to a patient with cutaneous gamma\/delta T-cell lymphoma and occult cirrhosis","volume":"83","author":"Avarbock","year":"2008","journal-title":"American Journal of Hematology"},{"issue":"13","key":"10.1002\/14651858.CD008946.pub3-BIB0138|cit138","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1001\/jama.1989.03420130044019","article-title":"Mycosis fungoides","volume":"261","author":"Bernstein","year":"1989","journal-title":"JAMA"},{"issue":"10","key":"10.1002\/14651858.CD008946.pub3-BIB0139|cit139","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1046\/j.1439-0353.2003.03711.x","article-title":"Bexarotene--an alternative therapy for progressive cutaneous T-cell lymphoma? First experiences","volume":"1","author":"Bohmeyer","year":"2003","journal-title":"Journal der Deutschen Dermatologischen Gesellschaft [Journal of the German Society of Dermatology]"},{"issue":"21","key":"10.1002\/14651858.CD008946.pub3-BIB0140|cit140","doi-asserted-by":"crossref","first-page":"5064","DOI":"10.1182\/blood-2008-10-184168","article-title":"Cutaneous lymphoma incidence patterns in the United States: a population-based study of 3884 cases","volume":"113","author":"Bradford","year":"2009","journal-title":"Blood"},{"issue":"1 Pt 1","key":"10.1002\/14651858.CD008946.pub3-BIB0141|cit141","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S0190-9622(87)70004-8","article-title":"Combined total body electron beam irradiation and chemotherapy for mycosis fungoides","volume":"16","author":"Braverman","year":"1987","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"4","key":"10.1002\/14651858.CD008946.pub3-BIB0142|cit142","first-page":"725","article-title":"Report of the committee on staging and classification of cutaneous T-cell lymphomas","volume":"63","author":"Lamberg","year":"1979","journal-title":"Cancer Treatment Reports"},{"issue":"3","key":"10.1002\/14651858.CD008946.pub3-BIB0143|cit143","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1159\/000017917","article-title":"Acrocyanosis induced by interferon alpha(2a)","volume":"196","author":"Campo-Voegeli","year":"1998","journal-title":"Dermatology"},{"issue":"16","key":"10.1002\/14651858.CD008946.pub3-BIB0144|cit144","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.1002\/cncr.28712","article-title":"Progressive multifocal leukoencephalopathy associated with brentuximab vedotin therapy: a report of 5 cases from the Southern Network on Adverse Reactions (SONAR) project","volume":"120","author":"Carson","year":"2014","journal-title":"Cancer"},{"issue":"3","key":"10.1002\/14651858.CD008946.pub3-BIB0145|cit145","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1200\/JCO.1993.11.3.570","article-title":"The Functional Assessment of Cancer Therapy scale: development and validation of the general measure","volume":"11","author":"Cella","year":"1993","journal-title":"Journal of Clinical Oncology"},{"issue":"1","key":"10.1002\/14651858.CD008946.pub3-BIB0146|cit146","doi-asserted-by":"publisher","first-page":"2","DOI":"10.12788\/j.sder.2018.002","article-title":"Mycosis fungoides - clinical and histopathologic features, differential diagnosis, and treatment","volume":"37","author":"Cerroni","year":"2018","journal-title":"Seminars in Cutaneous Medicine and Surgery"},{"issue":"20","key":"10.1002\/14651858.CD008946.pub3-BIB0147|cit147","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1001\/jama.291.20.2457","article-title":"Empirical evidence for selective reporting of outcomes in randomized trials: comparison of protocols to published articles","volume":"291","author":"Chan","year":"2004","journal-title":"JAMA"},{"issue":"3","key":"10.1002\/14651858.CD008946.pub3-BIB0148|cit148","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s11060-017-2389-9","article-title":"Characterization of the peripheral neuropathy associated with brentuximab vedotin treatment of Mycosis Fungoides and S\u00e9zary Syndrome","volume":"132","author":"Corbin","year":"2017","journal-title":"Journal of Neuro-oncology"},{"issue":"7","key":"10.1002\/14651858.CD008946.pub3-BIB0149|cit149","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1001\/archderm.143.7.854","article-title":"Incidence of cutaneous T-cell lymphoma in the United States, 1973-2002","volume":"143","author":"Criscione","year":"2007","journal-title":"Archives of Dermatology"},{"issue":"3","key":"10.1002\/14651858.CD008946.pub3-BIB0150|cit150","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1001\/archderm.1973.01620180079025","article-title":"Urticaria and anaphylactoid reactions after topical application of mechlorethamine","volume":"107","author":"Daughters","year":"1973","journal-title":"Archives of Dermatology"},{"issue":"1","key":"10.1002\/14651858.CD008946.pub3-BIB0151|cit151","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1093\/ije\/dyp174","article-title":"How to assess the external validity of therapeutic trials: a conceptual approach","volume":"39","author":"Dekkers","year":"2010","journal-title":"International Journal of Epidemiology"},{"issue":"3","key":"10.1002\/14651858.CD008946.pub3-BIB0152|cit152","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/0360-3016(88)90306-9","article-title":"Total skin electron irradiation for mycosis fungoides: relationship between acute toxicities and measured dose at different anatomic sites","volume":"15","author":"Desai","year":"1988","journal-title":"International Journal of Radiation Oncology, Biology, Physics"},{"issue":"29","key":"10.1002\/14651858.CD008946.pub3-BIB0153|cit153","doi-asserted-by":"crossref","first-page":"4492","DOI":"10.1200\/JCO.2010.29.3241","article-title":"Allogeneic hematopoietic cell transplantation for patients with mycosis fungoides and S\u00e9zary syndrome: a retrospective analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.","volume":"28","author":"Duarte","year":"2010","journal-title":"Journal of Clinical Oncology"},{"issue":"19","key":"10.1002\/14651858.CD008946.pub3-BIB0154|cit154","doi-asserted-by":"crossref","first-page":"4541","DOI":"10.1002\/cncr.25377","article-title":"Interim report of a phase 2 clinical trial of lenalidomide for T-cell non-Hodgkin lymphoma","volume":"116","author":"Dueck","year":"2010","journal-title":"Cancer"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD008946.pub3-BIB0155|cit155","doi-asserted-by":"crossref","first-page":"ii72","DOI":"10.1093\/annonc\/mdn095","article-title":"Primary cutaneous lymphoma: ESMO clinical recommendations for diagnosis, treatment and follow-up","volume":"19","author":"Dummer","year":"2008","journal-title":"Annals of Oncology"},{"issue":"33","key":"10.1002\/14651858.CD008946.pub3-BIB0156|cit156","doi-asserted-by":"crossref","first-page":"4091","DOI":"10.1200\/JCO.2011.39.8065","article-title":"Prospective international multicenter phase II trial of intravenous pegylated liposomal doxorubicin monochemotherapy in patients with stage IIB, IVA, or IVB advanced mycosis fungoides: final results from EORTC 21012","volume":"30","author":"Dummer","year":"2012","journal-title":"Journal of Clinical Oncology"},{"issue":"9","key":"10.1002\/14651858.CD008946.pub3-BIB0157|cit157","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1200\/JCO.2001.19.9.2456","article-title":"Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results","volume":"19","author":"Duvic","year":"2001","journal-title":"Journal of Clinical Oncology"},{"issue":"4","key":"10.1002\/14651858.CD008946.pub3-BIB0158|cit158","doi-asserted-by":"crossref","first-page":"222","DOI":"10.3816\/CLM.2002.n.003","article-title":"Quality-of-life improvements in cutaneous T-cell lymphoma patients treated with denileukin diftitox (ONTAK)","volume":"2","author":"Duvic","year":"2002","journal-title":"Clinical Lymphoma"},{"issue":"3","key":"10.1002\/14651858.CD008946.pub3-BIB0159|cit159","doi-asserted-by":"crossref","first-page":"514","DOI":"10.3109\/10428194.2012.720372","article-title":"Efficacy and safety of denileukin diftitox retreatment in patients with relapsed cutaneous T-cell lymphoma","volume":"54","author":"Duvic","year":"2013","journal-title":"Leukemia & Lymphoma"},{"issue":"32","key":"10.1002\/14651858.CD008946.pub3-BIB0160|cit160","doi-asserted-by":"crossref","first-page":"3759","DOI":"10.1200\/JCO.2014.60.3787","article-title":"Results of a phase II trial of brentuximab vedotin for CD30+ cutaneous T-cell lymphoma and lymphomatoid papulosis","volume":"33","author":"Duvic","year":"2015","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD008946.pub3-BIB0161|cit161","volume-title":"WHO Classification of Skin Tumours (4th edition)","author":"Elder","year":"2018"},{"issue":"4","key":"10.1002\/14651858.CD008946.pub3-BIB0162|cit162","doi-asserted-by":"crossref","first-page":"298","DOI":"10.3816\/CLM.2001.n.005","article-title":"Biological correlates of acute hypersensitivity events with DAB(389)IL-2 (denileukin diftitox, ONTAK) in cutaneous T-cell lymphoma: decreased frequency and severity with steroid premedication","volume":"1","author":"Foss","year":"2001","journal-title":"Clinical Lymphoma"},{"issue":"3","key":"10.1002\/14651858.CD008946.pub3-BIB0163|cit163","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1111\/bjd.17240","article-title":"British Association of Dermatologists and U.K. Cutaneous Lymphoma Group guidelines for the management of primary cutaneous lymphomas 2018","volume":"180","author":"Gilson","year":"2019","journal-title":"British Journal of Dermatology"},{"issue":"5","key":"10.1002\/14651858.CD008946.pub3-BIB0164|cit164","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1111\/j.1600-0536.1990.tb01614.x","article-title":"Local bullous reaction to topical mechlorethamine (mustine)","volume":"22","author":"Goday","year":"1990","journal-title":"Contact Dermatitis"},{"key":"10.1002\/14651858.CD008946.pub3-BIB0165|cit165","unstructured":"McMaster University (developed by Evidence Prime) GRADEpro GDT 2015"},{"issue":"4","key":"10.1002\/14651858.CD008946.pub3-BIB0166|cit166","first-page":"48","article-title":"Biotech Baddies","volume":"23","author":"Grant","year":"2009","journal-title":"The Scientist"},{"issue":"1","key":"10.1002\/14651858.CD008946.pub3-BIB0167|cit167","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/j.1365-2133.1976.tb04350.x","article-title":"Contact urticaria and anaphylactoid reaction induced by topical application of nitrogen mustard","volume":"94","author":"Grunnet","year":"1976","journal-title":"British Journal of Dermatology"},{"issue":"1-2","key":"10.1002\/14651858.CD008946.pub3-BIB0168|cit168","first-page":"59","article-title":"Perforating follicular mucinosis and immediate hypersensitivity to mechlorethamine in a patient with mycosis fungoides","volume":"107","author":"Guilhou","year":"1980","journal-title":"Annales de Dermatologie et de Venereologie"},{"issue":"7650","key":"10.1002\/14651858.CD008946.pub3-BIB0169|cit169","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"issue":"13","key":"10.1002\/14651858.CD008946.pub3-BIB0170|cit170","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1001\/jama.1983.03330370053031","article-title":"If nothing goes wrong, is everything all right? Interpreting zero numerators","volume":"249","author":"Hanley","year":"1983","journal-title":"JAMA"},{"issue":"2 Pt 1","key":"10.1002\/14651858.CD008946.pub3-BIB0171|cit171","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/0190-9622(95)90241-4","article-title":"Treatment of mycosis fungoides with photochemotherapy (PUVA): long-term follow-up","volume":"33","author":"Herrmann","year":"1995","journal-title":"Journal of the American Academy of Dermatology"},{"key":"10.1002\/14651858.CD008946.pub3-BIB0172|cit172","unstructured":"Higgins JP Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"issue":"7211","key":"10.1002\/14651858.CD008946.pub3-BIB0173|cit173","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1136\/bmj.319.7211.670","article-title":"What is meant by intention to treat analysis? Survey of published randomised controlled trials","volume":"319","author":"Hollis","year":"1999","journal-title":"BMJ"},{"issue":"11","key":"10.1002\/14651858.CD008946.pub3-BIB0174|cit174","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1200\/JCO.1987.5.11.1796","article-title":"Mycosis fungoides: management with topical nitrogen mustard","volume":"5","author":"Hoppe","year":"1987","journal-title":"Journal of Clinical Oncology"},{"issue":"8","key":"10.1002\/14651858.CD008946.pub3-BIB0175|cit175","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/j.ctrv.2014.06.005","article-title":"Systematic review of combination therapies for mycosis fungoides","volume":"40","author":"Humme","year":"2014","journal-title":"Cancer Treatment Reviews"},{"issue":"9616","key":"10.1002\/14651858.CD008946.pub3-BIB0176|cit176","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/S0140-6736(08)60420-1","article-title":"Mycosis fungoides and S\u00e9zary syndrome","volume":"371","author":"Hwang","year":"2008","journal-title":"Lancet"},{"issue":"1","key":"10.1002\/14651858.CD008946.pub3-BIB0177|cit177","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/j.1468-3083.2011.04011.x","article-title":"Comparison of pegylated interferon \u03b1-2b plus psoralen PUVA versus standard interferon \u03b1-2a plus PUVA in patients with cutaneous T-cell lymphoma","volume":"26","author":"H\u00fcsken","year":"2012","journal-title":"Journal of the European Academy of Dermatology and Venereology : JEADV"},{"key":"10.1002\/14651858.CD008946.pub3-BIB0178|cit178","volume-title":"Pathology and Genetics: Tumours of Hematopoetic and Lymphoid Tissues (World Health Organization Classification of Tumours)","author":"Jaffe","year":"2001"},{"issue":"7303","key":"10.1002\/14651858.CD008946.pub3-BIB0179|cit179","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1136\/bmj.323.7303.42","article-title":"Systematic reviews in health care: Assessing the quality of controlled clinical trials","volume":"323","author":"J\u00fcni","year":"2001","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD008946.pub3-BIB0180|cit180","first-page":"67","article-title":"A rare case of nephrotic syndrome revealing mycosis fungoide managed successfully with chemotherapy","volume":"12","author":"Kairouani","year":"2012","journal-title":"Pan African Medical Journal"},{"issue":"11","key":"10.1002\/14651858.CD008946.pub3-BIB0181|cit181","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1001\/archderm.1996.03890350051009","article-title":"Clinical stage IA (limited patch and plaque) mycosis fungoides. A long-term outcome analysis","volume":"132","author":"Kim","year":"1996","journal-title":"Archives of Dermatology"},{"issue":"7","key":"10.1002\/14651858.CD008946.pub3-BIB0182|cit182","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1001\/archderm.139.7.857","article-title":"Long-term outcome of 525 patients with mycosis fungoides and S\u00e9zary syndrome: Clinical prognostic factors and risk for disease progression","volume":"139","author":"Kim","year":"2003","journal-title":"Archives of Dermatology"},{"issue":"32","key":"10.1002\/14651858.CD008946.pub3-BIB0183|cit183","doi-asserted-by":"crossref","first-page":"3750-8","DOI":"10.1200\/JCO.2014.60.3969","article-title":"Phase II investigator-initiated study of brentuximab vedotin in mycosis fungoides and S\u00e9zary syndrome with variable CD30 expression level: a multi-institution collaborative project","volume":"33","author":"Kim","year":"2015","journal-title":"Journal of Clinical Oncology"},{"issue":"11","key":"10.1002\/14651858.CD008946.pub3-BIB0184|cit184","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1001\/jamadermatol.2013.5526","article-title":"Changing incidence trends of cutaneous T-cell lymphoma","volume":"149","author":"Korgavkar","year":"2013","journal-title":"JAMA Dermatology"},{"issue":"4","key":"10.1002\/14651858.CD008946.pub3-BIB0185|cit185","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1007\/s00105-007-1315-z","article-title":"Mycosis fungoides: Complications of long-term treatment with PUVA and ECP","volume":"58","author":"Korpusik","year":"2007","journal-title":"Hautarzt"},{"issue":"5","key":"10.1002\/14651858.CD008946.pub3-BIB0186|cit186","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1111\/j.1365-2133.1997.tb01138.x","article-title":"Oropharyngeal lichen planus associated with interferon-alpha treatment for mycosis fungoides: a rare side-effect in the therapy of cutaneous lymphomas","volume":"137","author":"K\u00fctting","year":"1997","journal-title":"British Journal of Dermatology"},{"issue":"2 Pt 1","key":"10.1002\/14651858.CD008946.pub3-BIB0187|cit187","first-page":"202","article-title":"Seizures during interferon alpha therapy: three cases in dermatology","volume":"130","author":"Legroux-Crespel","year":"2003","journal-title":"Annales de Dermatologie et de Venereologie"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD008946.pub3-BIB0188|cit188","first-page":"S84","article-title":"Positive results of a pivotal phase ii trial testing a manufactured 0.02% Mechlorethamine gel in mycosis fungoides (mf)","volume":"131","author":"Lessin","year":"2011","journal-title":"Journal of Investigative Dermatology"},{"issue":"9005","key":"10.1002\/14651858.CD008946.pub3-BIB0189|cit189","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/S0140-6736(96)91350-1","article-title":"Cutaneous T-cell lymphoma (mycosis fungoides)","volume":"347","author":"Lorincz","year":"1996","journal-title":"Lancet"},{"issue":"5","key":"10.1002\/14651858.CD008946.pub3-BIB0190|cit190","doi-asserted-by":"crossref","first-page":"E164","DOI":"10.1188\/12.CJON.E164-E172","article-title":"Adverse effects of denileukin diftitox and their management in patients with cutaneous T-cell lymphoma","volume":"16","author":"McCann","year":"2012","journal-title":"Clinical Journal of Oncology Nursing"},{"issue":"4","key":"10.1002\/14651858.CD008946.pub3-BIB0191|cit191","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/0360-3016(83)90063-9","article-title":"Combined moderate dose electron beam radiotherapy and topical chemotherapy for cutaneous T-Cell lymphoma","volume":"9","author":"Micaily","year":"1983","journal-title":"International Journal of Radiation Oncology, Biology, Physics"},{"issue":"2","key":"10.1002\/14651858.CD008946.pub3-BIB0192|cit192","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1002\/sim.4780040211","article-title":"Comparative analysis of two rates","volume":"4","author":"Miettinen","year":"1985","journal-title":"Statistics in Medicine"},{"issue":"1","key":"10.1002\/14651858.CD008946.pub3-BIB0193|cit193","doi-asserted-by":"crossref","first-page":"16","DOI":"10.5070\/D3221029801","article-title":"Methotrexate-induced necrolysis in tumoral-stage mycosis fungoides: a challenging diagnosis","volume":"22","author":"Mna","year":"2016","journal-title":"Dermatology Online Journal"},{"issue":"1","key":"10.1002\/14651858.CD008946.pub3-BIB0194|cit194","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/0197-2456(94)00031-W","article-title":"Assessing the quality of randomized controlled trials: An annotated bibliography of scales and checklists","volume":"16","author":"Moher","year":"1995","journal-title":"Controlled Clinical Trials"},{"issue":"10","key":"10.1002\/14651858.CD008946.pub3-BIB0195|cit195","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.jclinepi.2009.06.005","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"62","author":"Moher","year":"2009","journal-title":"Journal of Clinical Epidemiology"},{"issue":"1","key":"10.1002\/14651858.CD008946.pub3-BIB0196|cit196","doi-asserted-by":"crossref","first-page":"64","DOI":"10.2340\/00015555596468","article-title":"Mycosis fungoides plaque stage treated with topical nitrogen mustard with and without attempts at tolerance induction: report from the Scandinavian mycosis fungoides study group","volume":"59","author":"Molin","year":"1979","journal-title":"Acta Dermato-Venereologica"},{"issue":"1","key":"10.1002\/14651858.CD008946.pub3-BIB0197|cit197","first-page":"47","article-title":"Photochemotherapy (PUVA) in the pretumour stage of mycosis fungoides: a report from the Scandinavian Mycosis Fungoides Study Group","volume":"61","author":"Molin","year":"1981","journal-title":"Acta Dermatovenereologica (Stockholm)"},{"issue":"1","key":"10.1002\/14651858.CD008946.pub3-BIB0198|cit198","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1159\/000018423","article-title":"Mycosis fungoides: Review of epidemiological observations","volume":"201","author":"Morales Su\u00e1rez-Varela","year":"2000","journal-title":"Dermatology"},{"issue":"5","key":"10.1002\/14651858.CD008946.pub3-BIB0199|cit199","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.clml.2013.12.018","article-title":"Poorer prognosis of African-American patients with mycosis fungoides: an analysis of the SEER dataset, 1988 to 2008","volume":"14","author":"Nath","year":"2014","journal-title":"Clinical Lymphoma, Myeloma & Leukemia"},{"issue":"1","key":"10.1002\/14651858.CD008946.pub3-BIB0200|cit200","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/S0190-9622(97)70341-4","article-title":"Stevens-Johnson syndrome associated with topical nitrogen mustard therapy","volume":"36","author":"Newman","year":"1997","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"6","key":"10.1002\/14651858.CD008946.pub3-BIB0201|cit201","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1182\/blood-2007-03-055749","article-title":"Revisions to the staging and classification of mycosis fungoides and S\u00e9zary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC)","volume":"110","author":"Olsen","year":"2007","journal-title":"Blood"},{"issue":"18","key":"10.1002\/14651858.CD008946.pub3-BIB0202|cit202","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1200\/JCO.2010.32.0630","article-title":"Clinical end points and response criteria in mycosis fungoides and Sezary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer","volume":"29","author":"Olsen","year":"2011","journal-title":"Journal of Clinical Oncology"},{"issue":"1","key":"10.1002\/14651858.CD008946.pub3-BIB0203|cit203","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.jaad.2015.09.033","article-title":"Guidelines for phototherapy of mycosis fungoides and S\u00e9zary syndrome: A consensus statement of the United States Cutaneous Lymphoma Consortium","volume":"74","author":"Olsen","year":"2015","journal-title":"Journal of the American Academy of Dermatology"},{"key":"10.1002\/14651858.CD008946.pub3-BIB0204|cit204","unstructured":"Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5) 2014"},{"issue":"2","key":"10.1002\/14651858.CD008946.pub3-BIB0205|cit205","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1111\/j.1600-0609.2005.00497.x","article-title":"Long-term experience with low-dose interferon-alpha and PUVA in the management of early mycosis fungoides","volume":"75","author":"Rupoli","year":"2005","journal-title":"European Journal of Haematology"},{"issue":"12","key":"10.1002\/14651858.CD008946.pub3-BIB0206|cit206","first-page":"39","article-title":"Contact urticaria and anaphylactic reactions induced by topical application of nitrogen mustard","volume":"68","author":"S\u00e1nchez Yus","year":"1977","journal-title":"Actas Dermo-Sifiliograficas"},{"issue":"s66","key":"10.1002\/14651858.CD008946.pub3-BIB0207|cit207","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1046\/j.0366-077X.2003.05628.x","article-title":"Imiquimod: modes of action","volume":"149","author":"Sauder","year":"2003","journal-title":"British Journal of Dermatology"},{"issue":"5","key":"10.1002\/14651858.CD008946.pub3-BIB0208|cit208","doi-asserted-by":"crossref","first-page":"372","DOI":"10.7326\/0003-4819-109-5-372","article-title":"Histopathologic staging at initial diagnosis of mycosis fungoides and the S\u00e9zary syndrome. Definition of three distinctive prognostic groups","volume":"109","author":"Sausville","year":"1988","journal-title":"Annals of Internal Medicine"},{"issue":"8","key":"10.1002\/14651858.CD008946.pub3-BIB0209|cit209","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008908.pub3","article-title":"Allogeneic stem cell transplantation versus conventional therapy for advanced primary cutaneous T-cell lymphoma","author":"Schlaak","year":"2013","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"4","key":"10.1002\/14651858.CD008946.pub3-BIB0210|cit210","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1159\/000236781","article-title":"Glucocorticoid-induced apoptosis of lymphoid cells","volume":"105","author":"Schwartzman","year":"1994","journal-title":"International Archives of Allergy and Immunology"},{"issue":"2","key":"10.1002\/14651858.CD008946.pub3-BIB0211|cit211","first-page":"93","article-title":"Recombinant leukocyte interferon alfa-2a in the treatment of mycosis fungoides","volume":"1","author":"Simoni","year":"1987","journal-title":"Journal of Biological Regulators and Homeostatic Agents"},{"issue":"3","key":"10.1002\/14651858.CD008946.pub3-BIB0212|cit212","doi-asserted-by":"crossref","first-page":"e749","DOI":"10.1097\/MJT.0000000000000056","article-title":"Polish lymphoma research group experience with bexarotene in the treatment of cutaneous T-cell lymphoma","volume":"23","author":"Sokolowska-Wojdylo","year":"2016","journal-title":"American Journal of Therapeutics"},{"issue":"4","key":"10.1002\/14651858.CD008946.pub3-BIB0213|cit213","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.det.2015.05.008","article-title":"The use of interferons in the treatment of cutaneous T-cell lymphoma","volume":"33","author":"Spaccarelli","year":"2015","journal-title":"Dermatologic Clinics"},{"issue":"12","key":"10.1002\/14651858.CD008946.pub3-BIB0214|cit214","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/0021-9681(81)90058-8","article-title":"Measuring the quality of life of cancer patients: a concise QL-index for use by physicians","volume":"34","author":"Spitzer","year":"1981","journal-title":"Journal of Chronic Diseases"},{"issue":"3","key":"10.1002\/14651858.CD008946.pub3-BIB0215|cit215","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.clml.2012.01.011","article-title":"Pilot study of denileukin diftitox alternate dosing regimen in patients with cutaneous peripheral T-cell lymphomas","volume":"12","author":"Talpur","year":"2012","journal-title":"Clinical Lymphoma, Myeloma & Leukemia"},{"issue":"5","key":"10.1002\/14651858.CD008946.pub3-BIB0216|cit216","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1002\/cncr.29103","article-title":"Final report of a phase 2 clinical trial of lenalidomide monotherapy for patients with T-cell lymphoma","volume":"121","author":"Toumishey","year":"2015","journal-title":"Cancer"},{"issue":"8","key":"10.1002\/14651858.CD008946.pub3-BIB0217|cit217","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.ejca.2006.01.025","article-title":"EORTC consensus recommendations for the treatment of mycosis fungoides\/S\u00e9zary syndrome","volume":"42","author":"Trautinger","year":"2006","journal-title":"European Journal of Cancer"},{"key":"10.1002\/14651858.CD008946.pub3-BIB0218|cit218","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.ejca.2017.02.027","article-title":"European organisation for research and treatment of cancer consensus recommendations for the treatment of mycosis fungoides\/S\u00e9zary syndrome - Update 2017","volume":"77","author":"Trautinger","year":"2017","journal-title":"European Journal of Cancer"},{"issue":"4","key":"10.1002\/14651858.CD008946.pub3-BIB0219|cit219","first-page":"504","article-title":"Mycosis fungoides: Disease evolution and prognosis of 309 Dutch patients","volume":"136","author":"Doorn","year":"2000","journal-title":"Archives of Dermatology"},{"issue":"1","key":"10.1002\/14651858.CD008946.pub3-BIB0220|cit220","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1002\/1097-0142(197307)32:1<18::AID-CNCR2820320103>3.0.CO;2-Q","article-title":"Complete remissions of mycosis fungoides lymphoma induced by topical nitrogen mustard (HN2). Control of delayed hypersensitivity to HN2 by desensitization and by induction of specific immunologic tolerance","volume":"32","author":"Van Scott","year":"1973","journal-title":"Cancer"},{"key":"10.1002\/14651858.CD008946.pub3-BIB0221|cit221","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/j.1600-0609.1990.tb00903.x","article-title":"Interferon alpha-2a in cutaneous T-cell lymphoma","volume":"52","author":"Vegna","year":"1990","journal-title":"European Journal of Haematology. Supplementum"},{"issue":"12","key":"10.1002\/14651858.CD008946.pub3-BIB0222|cit222","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1016\/S0895-4356(98)00131-0","article-title":"The Delphi list: A criteria list for quality assessment of randomized clinical trials for conducting systematic reviews developed by Delphi consensus","volume":"51","author":"Verhagen","year":"1998","journal-title":"Journal of Clinical Epidemiology"},{"issue":"9","key":"10.1002\/14651858.CD008946.pub3-BIB0223|cit223","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1080\/10428190600709655","article-title":"S\u00e9zary cell counts in erythrodermic cutaneous T-cell lymphoma: Implications for prognosis and staging","volume":"47","author":"Vonderheid","year":"2006","journal-title":"Leukemia & Lymphoma"},{"issue":"10","key":"10.1002\/14651858.CD008946.pub3-BIB0224|cit224","doi-asserted-by":"crossref","first-page":"2282","DOI":"10.1002\/cncr.11780","article-title":"Outcome in 34 patients with juvenile-onset mycosis fungoides: A clinical, immunophenotypic, and molecular study","volume":"98","author":"Wain","year":"2003","journal-title":"Cancer"},{"issue":"1","key":"10.1002\/14651858.CD008946.pub3-BIB0225|cit225","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1001\/jama.1988.03410010050033","article-title":"Mycosis fungoides in the United States. Increasing incidence and descriptive epidemiology","volume":"260","author":"Weinstock","year":"1988","journal-title":"JAMA"},{"issue":"1","key":"10.1002\/14651858.CD008946.pub3-BIB0226|cit226","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1002\/(SICI)1097-0142(19990101)85:1<208::AID-CNCR28>3.0.CO;2-2","article-title":"The changing survival of patients with mycosis fungoides: A population-based assessment of trends in the United States","volume":"85","author":"Weinstock","year":"1999","journal-title":"Cancer"},{"issue":"6","key":"10.1002\/14651858.CD008946.pub3-BIB0227|cit227","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1111\/j.1365-2133.2003.05698.x","article-title":"Joint British Association of Dermatologists and U.K. Cutaneous Lymphoma Group guidelines for the management of primary cutaneous T-cell lymphomas","volume":"149","author":"Whittaker","year":"2003","journal-title":"British Journal of Dermatology"},{"issue":"1","key":"10.1002\/14651858.CD008946.pub3-BIB0228|cit228","first-page":"354","article-title":"EORTC classification for primary cutaneous lymphomas: a proposal from the Cutaneous Lymphoma Study Group of the European Organization for Research and Treatment of Cancer","volume":"90","author":"Willemze","year":"1997","journal-title":"Blood"},{"issue":"10","key":"10.1002\/14651858.CD008946.pub3-BIB0229|cit229","doi-asserted-by":"crossref","first-page":"3768","DOI":"10.1182\/blood-2004-09-3502","article-title":"WHO-EORTC classification for cutaneous lymphomas","volume":"105","author":"Willemze","year":"2005","journal-title":"Blood"},{"key":"10.1002\/14651858.CD008946.pub3-BIB0230|cit230","unstructured":"Willemze R Cerroni L Kempf W Berti E Facchetti F Swerdlow SH The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas Blood 10.1182\/blood-2018-11-881268"},{"issue":"8","key":"10.1002\/14651858.CD008946.pub3-BIB0231|cit231","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/j.bbmt.2009.04.017","article-title":"A meta-analysis of patients receiving allogeneic or autologous hematopoietic stem cell transplant in mycosis fungoides and Sezary syndrome","volume":"15","author":"Wu","year":"2009","journal-title":"Biology of Blood & Marrow Transplantation"},{"issue":"2","key":"10.1002\/14651858.CD008946.pub3-BIB0232|cit232","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/1523-1747.ep12329711","article-title":"Apoptosis induction of ultraviolet light A and photochemotherapy in cutaneous T-cell Lymphoma: relevance to mechanism of therapeutic action","volume":"107","author":"Yoo","year":"1996","journal-title":"Journal Investigative Dermatology"},{"issue":"3","key":"10.1002\/14651858.CD008946.pub3-BIB0233|cit233","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s11096-013-9756-1","article-title":"Cyclophosphamide-induced generalised reticulated skin pigmentation: a rare presentation","volume":"35","author":"Youssef","year":"2013","journal-title":"International Journal of Clinical Pharmacy"},{"issue":"4","key":"10.1002\/14651858.CD008946.pub3-BIB0234|cit234","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/S0190-9622(96)80062-4","article-title":"Low-dose methotrexate to treat erythrodermic cutaneous T-cell lymphoma: results in twenty-nine patients","volume":"34","author":"Zackheim","year":"1996","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"3","key":"10.1002\/14651858.CD008946.pub3-BIB0235|cit235","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/S0190-9622(99)70491-3","article-title":"Prognosis in cutaneous T-cell lymphoma by skin stage: Long-term survival in 489 patients","volume":"40","author":"Zackheim","year":"1999","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"1","key":"10.1002\/14651858.CD008946.pub3-BIB0236|cit236","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008946","article-title":"Interventions for mycosis fungoides","author":"Weberschock","year":"2011","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"9","key":"10.1002\/14651858.CD008946.pub3-BIB0237|cit237","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008946.pub2","article-title":"Interventions for mycosis fungoides","author":"Weberschock","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2024,8,9]],"date-time":"2024-08-09T11:30:43Z","timestamp":1723203043000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD008946.pub3"}},"subtitle":[],"editor":[{"name":"Cochrane Skin Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2020,7,7]]},"references-count":237,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2020,7]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd008946.pub3","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,7]]}}}